Sanofi Taxotere Eye Injury Patients Urge Court to Advance Suits

July 29, 2022, 3:39 PM UTC

Taxotere patients alleging the breast cancer drug caused irreversible eye injury urged a federal court in Louisiana to advance their claims, saying Sanofi US Services Inc. has failed to show that it adequately warned doctors about the risk of permanent excessive tearing or that federal law blocks the litigation.

Whether the Taxotere label was adequate is an inherently factual question that is premature to decide on the pleadings, the patients told the US District Court for the Eastern District of Louisiana Thursday.

A warning that Taxotere can cause permanent harm because of tear duct blockage would have encouraged their referral ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.